(thirdQuint)Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC.

 Patients will receive AZD9291 at a dose of 80 mg once daily.

 Systemic evaluation will be done by PET-CT scan after 6 weeks.

 In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks.

 Non-responding patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of response assessment at each time-point).

 All the patients will be followed for 2 years.

 The imaging modality used for RECIST v1.

1 assessments will be PET-CT scan.

.

 Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC@highlight

Patients will receive AZD9291 at a dose of 80 mg once daily.

 Systemic evaluation will be done by PET-CT scan after 6 weeks.

 In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks.

 Non-responding patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of response assessment at each time-point).

